Conference Track

Pharmacology and Drug-drug Interactions

Source: CCO Independent Conference Coverage of the 2003 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Expert Analysis

Pharmacology & Drug-Drug Interactions

Program Director: John P. Phair, MD

Faculty:

Edward P. Acosta, PharmD
Stephen L. Becker, MD
Courtney V. Fletcher, PharmD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new data on dosing regimens and drug-drug interactions of selected approved and investigational antiretrovirals
Review the clinical significance of emerging data on renal toxicity associated with tenofovir
Describe the effect of food of nelfinavir exposures

Earn CME credit by reading the expert analysis and commentary on the antiretroviral management of patients receiving therapy. Topics covered include:

Atazanavir dosing and interactions
Didanosine dose adjustment when coadministered by tenofovir
Effect of food on nelfinavir exposures
Renal toxicity associated with tenofovir
Lopinavir/ritonavir plus phenytoin
Other interactions: tipranavir and T-20

CREDIT INFORMATION

Release Date: 03/06/03

Expiration Date: 03/05/04

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.